Table 1.
Demographic and Clinical Characteristics of HLA-Matched Validation and Training Cohorts
| Characteristic | No. (%) | P | |
|---|---|---|---|
| Training (n = 1,151) | Validation (n = 580) | ||
| Age, years | .67 | ||
| Median | 56 | 56 | |
| Range | 18-77 | 19-77 | |
| Male sex | 693 (60) | 352 (61) | .85 |
| KPS, % | .88 | ||
| 90-100 | 702 (61) | 361 (62) | |
| < 90 | 386 (34) | 188 (32) | |
| Missing | 63 (5) | 31 (5) | |
| Secondary disorder | .93 | ||
| No | 898 (78) | 448 (77) | |
| Yes | 222 (19) | 116 (20) | |
| Missing | 31 (3) | 16 (3) | |
| Cytogenetic status | .92 | ||
| MK positive | 195 (17) | 94 (16) | |
| Very good | 9 (< 1) | 7 (1) | |
| Good | 440 (38) | 233 (40) | |
| Intermediate | 272 (24) | 131 (23) | |
| Poor | 128 (11) | 62 (11) | |
| Very poor | 21 (2) | 13 (2) | |
| Missing | 86 (7) | 40 (7) | |
| Blast in marrow before HCT, % | .84 | ||
| ≤ 2 | 497 (43) | 239 (41) | |
| 2-5 | 236 (21) | 121 (21) | |
| 5-10 | 209 (18) | 105 (18) | |
| > 10 | 90 (8) | 45 (8) | |
| Missing | 119 (10) | 70 (12) | |
| Blast in blood before HCT, % | .67 | ||
| ≤ 3 | 877 (76) | 448 (77) | |
| > 3 | 89 (8) | 38 (7) | |
| Missing | 185 (16) | 94 (16) | |
| Platelet count before HCT, × 109/L | .84 | ||
| ≤ 50 | 489 (42) | 242 (42) | |
| > 50 | 658 (57) | 335 (58) | |
| Missing | 4 (< 1) | 3 (< 1) | |
| ANC before HCT, /μL | .50 | ||
| ≥ 800 | 682 (59) | 347 (60) | |
| < 800 | 420 (36) | 215 (37) | |
| Missing | 49 (4) | 18 (3) | |
| Elevated LDH before HCT | .87 | ||
| No | 677 (59) | 346 (60) | |
| Yes | 327 (28) | 165 (28) | |
| Missing | 147 (13) | 69 (12) | |
| IPSS at diagnosis | .71 | ||
| Low | 28 (2) | 13 (2) | |
| Intermediate-1 | 412 (36) | 215 (37) | |
| Intermediate-2 | 381 (33) | 202 (35) | |
| High | 98 (9) | 40 (7) | |
| Missing | 232 (20) | 110 (19) | |
| Pretransplantation therapy | .55 | ||
| Hypomethylating agents only | 378 (33) | 189 (33) | |
| Chemotherapy only | 71 (6) | 33 (6) | |
| Both | 23 (2) | 19 (3) | |
| None | 646 (56) | 325 (56) | |
| Missing | 33 (3) | 14 (2) | |
| Conditioning regimen intensity | .89 | ||
| Myeloablative | 662 (58) | 334 (58) | |
| Reduced | 338 (29) | 174 (30) | |
| Nonmyeloablative | 127 (11) | 63 (11) | |
| Missing | 24 (2) | 9 (2) | |
| Graft type | .64 | ||
| Bone marrow | 221 (19) | 106 (18) | |
| Peripheral blood | 930 (81) | 474 (82) | |
| Ex vivo T-cell depletion | 29 (3) | 11 (2) | .93 |
| ATG or alemtuzumab | 335 (29) | 174 (30) | .09 |
| Type of donor | .92 | ||
| Sibling | 491 (43) | 246 (42) | |
| Unrelated | 660 (57) | 334 (58) | |
Abbreviations: ANC, absolute neutrophil count; ATG, antithymocyte globulin; HCT, hematopoietic cell transplantation; IPSS, International Prognostic Scoring System; KPS, Karnofsky performance status; LDH, lactate dehydrogenase; MK, monosomal karyotype.